These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33244378)

  • 41. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins and the COVID-19 main protease:
    Reiner Ž; Hatamipour M; Banach M; Pirro M; Al-Rasadi K; Jamialahmadi T; Radenkovic D; Montecucco F; Sahebkar A
    Arch Med Sci; 2020; 16(3):490-496. PubMed ID: 32399094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
    Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
    Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
    Varadharajan V; Arumugam GS; Shanmugam S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
    Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.
    Mathpal S; Joshi T; Sharma P; Joshi T; Pundir H; Pande V; Chandra S
    J Biomol Struct Dyn; 2022 Feb; 40(3):1084-1100. PubMed ID: 32940134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA.
    Arif MN
    Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation.
    Jahantigh H; Ahmadi N; Lovreglio P; Stufano A; Enayatkhani M; Shahbazi B; Ahmadi K
    J Biomol Struct Dyn; 2023 Jul; 41(11):5057-5066. PubMed ID: 35612907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.
    Paul AS; Islam R; Parves MR; Mamun AA; Shahriar I; Hossain MI; Hossain MN; Ali MA; Halim MA
    J Biomol Struct Dyn; 2022 Mar; 40(4):1639-1658. PubMed ID: 33047658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of alkaloids from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Mol Struct; 2021 Apr; 1229():129489. PubMed ID: 33100380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition.
    Mir SA; Meher RK; Nayak B
    Biochem Biophys Rep; 2023 Jul; 34():101459. PubMed ID: 36987522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
    Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
    Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.
    Khater I; Nassar A
    Biochem Biophys Rep; 2021 Sep; 27():101032. PubMed ID: 34099985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
    Bharadwaj S; Dubey A; Yadava U; Mishra SK; Kang SG; Dwivedi VD
    Brief Bioinform; 2021 Mar; 22(2):1361-1377. PubMed ID: 33406222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.